Respiratory Diseases Drugs Market to Decline in 2021, but Expected to Recover and Reach $98.81 Billion by 2025

Strategic Insights -

The global respiratory diseases drugs market is expected to decline in 2021, due to the stabilization of output by companies after the COVID-19 pandemic in 2020. However, the market is expected to recover and reach $98.81 billion by 2025 at a compound annual growth rate (CAGR) of 5%. Companies are increasingly using biomarkers in the drug development process, and are investing in personalized medicine for customized treatment of respiratory diseases.

Key Takeaways:

  • The global respiratory diseases drugs market is expected to decline from $90.32 billion in 2020 to $79.82 billion in 2021 at a CAGR of -11.6%.
  • The market is expected to reach $98.81 billion in 2025 at a CAGR of 5%.
  • Companies in the respiratory drugs market are increasingly using biomarkers in the drug development process, reducing the time taken to bring the product into the market.
  • Companies are investing in personalized medicine for customized treatment of respiratory diseases, aiming to provide medical care according to the patient's individual characteristics and genetic makeup.
  • Key companies in the industry include GlaxosmithKline Plc, AstraZeneca Plc, Merck & Co, Novartis AG, and Johnson & Johnson.
  • The market is segmented into anti-asthmatics and copd drugs, and cough and cold preparations.
  • North America was the largest region in the global respiratory diseases drugs market, accounting for 48% of the market in 2020.
  • The use of biomarkers in the drug development process can help predict the drug efficacy faster than conventional clinical endpoints.
  • Companies such as Genentech and Janssen are investing in the use of biomarkers for understanding the efficacy of potential respiratory drug.
  • Companies in the respiratory drugs market are also offering drugs for customized individual treatment for better treatment against respiratory diseases.

Statistics:

  • Global respiratory diseases drugs market size: $90.32 billion (2020), $79.82 billion (2021), and $98.81 billion (2025)
  • CAGR: -11.6% (2020-2021), 5% (2021-2025)
  • Companies in the market are investing in biomarkers to reduce the time taken to bring the product into the market (by 30-40%)
  • Share of North America in the global market: 48% (2020)
  • Share of Western Europe in the global market: 19% (2020)
  • Share of Africa in the global market: smallest region (2020)

Sources:

  • "Respiratory Diseases Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report
  • ResearchAndMarkets.com
  • BusinessWire.com
  • GlaxosmithKline Plc
  • AstraZeneca Plc
  • Merck & Co
  • Novartis AG
  • Johnson & Johnson